Working… Menu
Trial record 1 of 11 for:    Sheba | Chronic Myeloid Leukemia | Israel
Previous Study | Return to List | Next Study

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02115672
Recruitment Status : Withdrawn (loss of support)
First Posted : April 16, 2014
Last Update Posted : August 15, 2016
Information provided by (Responsible Party):
Sheba Medical Center

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : November 2016
Estimated Study Completion Date : November 2018